top of page
JPG 96 KB

The world’s first medical-grade home-monitoring solution for hypothyroidism

ThyroidSense
Hypothyroidism

Hypothyroidism and the lack of patient-focused monitoring tools 

Chronic hypothyroidism affects more than 250 million people globally. Today, patients are required to make frequent visits to the hospital for blood-tests to monitor their condition and regulate medication to maintain a healthy and productive life. This approach to disease mangement poses significant health challenges for patients.

Better regulation of medication is key to improved care

15%

increase in patient risks for developing comorbidities such as diabetes from six months of poor regulation of medication*

33%

of patients experience poor regulation of medication to an extend it increases risk of sickness and comorbidities today**

$50B

is the estimated societal cost of poorly regulated patients in the United States

Solution

Meet ThyroidSense

HEI ThyroidSense enables patients to monitor their condition in real-time from the comfort of their home and receive remote care

HEI Telemedicine.png

Steen Bonnema

 Odense University Hospital Professor in Endocrinology, Southern University of Denmark

”15-20% of patients continue to experience low quality-of-life despite medication. Today, we can do very little to help these patients. With a patient-empowerment solution new dimensions can be added to help patients master their condition. [...] 90-95% of patients with hypothyroidism have the capabilities to adjust and optimize medication from their home should a medical-grade monitoring device be available."

Bente Julie Lasserre

Deputy Chairman of Danish Thyroid Association 

& patient

“Improvements in medical practices that can help catch patients earlier is highly valuable as this increases likelihood for getting back to a living a normal life with the condition. [...] The ability to measure TSH, monitor symptoms and wellbeing, and having a digital assistant to help adhere to medication plans, diet, exercise etc. is highly valuable for patients."

 

Marina Tarasova.png

Marina Tarasova

COO of Paloma, Leading Thyroid Telemedicine Company (US)

“Our patients would highly appreciate an easy and quick way to monitor their thyroid hormone levels to stay on top of their care. [...] Being able to see test results instantly, while the patient is in the office or in a telehealth interaction could significantly improve the patient and doctor experience."

About

About

We are an experienced team of scientific, clinical, and commercial profiles working hard on our mission to make it easy for patients with hypothyroidism to master their condition to live a healthy and productive life. Feel free to reach out to the team with input and collaboration opportunities. 

Jesper_edited.png

Jesper Kimer

  • LinkedIn

Chief Executive Officer & Co-Founder

Winnie_edited.jpg

Winnie Edith Svendsen

  • LinkedIn

Chief Scientific Officer & Co-Founder

Dan_edited.jpg

Dan Høgdall

  • LinkedIn

Chief Clinical Officer & Co-Founder

Jamie_edited.jpg

Jaime Castillo-León

  • LinkedIn

Chief Development Officer

Alemnew_edited.jpg

Alemnew Mekonnen

  • LinkedIn

Senior Electrochemist

Line_edited.jpg

Line Andresen

  • LinkedIn

Bioinformatician

Kumaravel.png

Kumaravel Shanmugavel

  • LinkedIn

Senior Scientist

Supported By

Bio Innovation Institute
Bio Innovation Institute
Bio Innovation Institute
Bio Innovation Institute
Bio Innovation Institute
Bio Innovation Institute
Bio Innovation Institute

*Lillevang-Johansen et al. Eur J Endocrinol. 2019;180:407-416. 

**Laulund et al. PLoS One. 2014;9:e110437. 

HEI Therapeutics Logo.png

HEI Therapeutics ApS 

Ole Maaløes Vej 3, 3 floor

DK 2200, Copenhagen N

Denmark

hello@hei.care

+45 20689096

CVR: 4261 3207

© 2023 by HEI Therapeutics

  • LinkedIn
  • YouTube
bottom of page